This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Elaine M. Sloand, MD; Elisabeth Pitt, MA; Harvey G. Klein, MD

JAMA. 1995;274(17):1368-1373.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THE YEARS following the emergence of the human immunodeficiency virus type 1 (HIV-1) infection as a transfusion-transmitted disease, both the general public and the medical profession have voiced great concern about the safety of the blood supply. Although improved donor screening and testing have greatly increased blood safety, a 1993 Gallup survey¹ showed that concern about acquired immunodeficiency syndrome (AIDS) far exceeded that for heart or lung disease, despite the greater health risk these latter pose. Widely publicized shortcomings in the conduct of several blood collecting agencies in Europe and the United States have only heightened public fear. As the number of measures to promote safety increases, their value must be weighed against many other considerations, such as wastage of discarded blood and unnecessary loss of potential donors due to false-positive results, direct costs of additional or more technologically demanding tests, the increased risk of errors with additional . . . [Full Text PDF of this Article]

Author Affiliations
From the National Heart, Lung, and Blood Institute (Dr Sloand and Ms Pitt) and Warren Grant Magnuson Clinical Center (Dr Klein), Bethesda, Md.

Footnotes
Reprint requests to National Heart, Lung, and Blood Institute, 31 Center Dr, MSC 2490, Bldg 31, Room 4A11, Bethesda, MD 20892-2490 (Dr Sloand).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?